Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic trioxide combined with decitabine for low/intermediate-risk myelodysplastic syndrome
ChiCTR1800016234Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide and decitabine in myelodysplastic syndrome (MDS), sponsored by Henan Cancer Hospital. Primary endpoint: overall response rate. Started May 2018; status: recruiting.
02
Drugs
arsenic trioxidedecitabine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR1800016234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016234.